Business
ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions
ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions\n\nViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions\n\n\nClinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa \n\n LOS ANGELES, CA--(Marketwired - November 30, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA registered drug, Viabecline. Significant results have been achieved in just 10 days of treatment using ViaDerma's proprietary transdermal delivery system. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas. The \"Patent Pending Transdermal System\" can deliver medications and nutrients into the body through the skin. For example, a deep wound with the hip bone exposed, had significant healing results, at the Dar Al Zahraa Hospital in Tripoli, Lebanon, after just 10 days. ViaDerma is seeing amazing penetration and absorption with localized wound treatment. \"We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido,\" said CEO Dr. Christopher Otiko.Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can...